The first 60 days: Metastatic and recurrent anal squamous cell carcinoma
Metastatic anal cancer is squamous cell anal cancer that has spread to the liver, lungs or distant lymph nodes, or come back where surgery can no longer remove it. Carboplatin with paclitaxel became the standard first treatment after the InterAACT trial, the PD-1 antibody retifanlimab was added to it in 2025 after POD1UM-303, and nivolumab or pembrolizumab are options after chemotherapy. Below, week by week, is what OnCo's record of Metastatic and recurrent anal squamous cell carcinoma says about the first two months: the order is typical, the timing is yours to ask about. Sections appear only where the record has something to say. Orientation, not medical advice.
What happens now
Staging tests establish exactly what and where the cancer is. Everything else follows from the answers.
Ask which of these were tested and what the results were; see the report reader for what each value means.
These specialties appear in the standard of care for this cancer. In most centres they meet weekly as a tumour board to agree each plan; you can ask when yours was discussed and what was decided.
- PathologistNamed in the standard of care for: Oligometastatic disease.
- SurgeonNamed in the standard of care for: Oligometastatic disease, Isolated pelvic recurrence.
- Medical oncologistNamed in the standard of care for: First line, After platinum chemotherapy, Oligometastatic disease.
- Clinical oncologist (radiotherapy)Named in the standard of care for: Oligometastatic disease, Isolated pelvic recurrence.
A second opinion from a centre that treats many similar cases is normal, not rude; the standard of care tells you what to compare it against.
Each row is a setting from the standard of care, in the order it usually arises. Not all will apply to you; your stage and biomarkers decide which do. The guideline grade, where recorded, says how strong the evidence is.
Carboplatin and paclitaxel with retifanlimab (POD1UM-303, approved 2025); carboplatin and paclitaxel alone (InterAACT) where the antibody is unavailable or contraindicated.
Resection or stereotactic radiotherapy of limited liver or lung metastases alongside systemic therapy, on a case basis.
Salvage abdominoperineal resection when the tumour is resectable; re-irradiation is rarely possible.
Nivolumab (NCI9673) or pembrolizumab (KEYNOTE-158) if no prior PD-1 antibody; fluorouracil-based or taxane chemotherapy otherwise.
Generated from this cancer's standard of care, biomarkers and open problems. Take the group that matches where you are. To tick, add your own and print, open the one-page appointment sheet.
Newly diagnosed
- What is my exact diagnosis, stage, and grade, and which tests established them?Everything else follows from an accurate stage and subtype.
- Which biomarkers have been tested on my tumour (for example HPV and p16 status, PD-L1, Circulating HPV DNA, HIV status and CD4 count, Mismatch repair and tumour mutational burden), and what were the results?These results decide eligibility for targeted therapy, immunotherapy, and trials.
- Which subtype is my cancer, and does that change the recommended treatment?Recognised subtypes for this cancer include Synchronous metastatic anal squamous cell carcinoma, Metachronous relapse after chemoradiotherapy, Inoperable locally recurrent anal cancer.
- Is germline (inherited) genetic testing recommended for me or my family?Inherited variants can change treatment and matter for relatives.
First line
- For my situation (first line), which of the standard options do you recommend and why?Guideline options include: Carboplatin and paclitaxel with retifanlimab (POD1UM-303, approved 2025); carboplatin and paclitaxel alone (InterAACT) where the antibody is unavailable or contraindicated.
- Am I a candidate for Carboplatin, Paclitaxel / nab-paclitaxel, Retifanlimab, and what side effects should I expect?Knowing the expected toxicities helps you plan work, family, and supportive care.
After platinum chemotherapy
- For my situation (after platinum chemotherapy), which of the standard options do you recommend and why?Guideline options include: Nivolumab (NCI9673) or pembrolizumab (KEYNOTE-158) if no prior PD-1 antibody; fluorouracil-based or taxane chemotherapy otherwise.
- Am I a candidate for Nivolumab, Pembrolizumab, Fluorouracil (5-FU), and what side effects should I expect?Knowing the expected toxicities helps you plan work, family, and supportive care.
Oligometastatic disease
- For my situation (oligometastatic disease), which of the standard options do you recommend and why?Guideline options include: Resection or stereotactic radiotherapy of limited liver or lung metastases alongside systemic therapy, on a case basis.
Isolated pelvic recurrence
- For my situation (isolated pelvic recurrence), which of the standard options do you recommend and why?Guideline options include: Salvage abdominoperineal resection when the tumour is resectable; re-irradiation is rarely possible.
Any stage
- Are there clinical trials I could join, for example of Retifanlimab, Circulating tumour HPV DNA (ctHPV-DNA), Nivolumab, Pembrolizumab?Trials are how the next standard of care is set; asking early keeps options open.
- Would a second opinion at a high-volume centre change anything, and can you help arrange it?Rare or high-stakes decisions benefit from a centre that treats many similar patients.
- What supportive care (symptom control, nutrition, exercise, mental health, financial help) is available from the start?Supportive care improves quality of life and helps patients complete treatment.
- I read that “Median survival remains under two years even with a PD-1 antibody added to chemotherapy”. How does that affect my plan?Open problems are where trials and second opinions matter most.
- I read that “No second-line standard exists after chemo-immunotherapy”. How does that affect my plan?Open problems are where trials and second opinions matter most.
Much of what helps in the first weeks is free if you know to ask: testing, helplines, rides and lodging, second opinions, trial travel.
- Metastatic and recurrent anal squamous cell carcinoma: the full pageMetastatic anal cancer is squamous cell anal cancer that has spread to the liver, lungs or distant lymph nodes, or come back where surgery can no longer remove it. Carboplatin with paclitaxel became the standard first treatment after the InterAACT trial, the PD-1 antibody retifanlimab was added to it in 2025 after POD1UM-303, and nivolumab or pembrolizumab are options after chemotherapy.
- One-page appointment sheetYour questions, the words you may hear, what to bring, and space for the answers. Print it.
- Treatment sequencingWhich treatment tends to follow which, line by line.
- NavigatorStandard of care for your stage, what you have tried, and trials near you.
- Re-irradiation: Giving radiotherapy again to a region that has already been treated, once thought impossible because normal tissues remember the first dose.
- HPV-positive (p16) head and neck cancer: Throat cancers caused by the human papillomavirus, identified by a p16 stain.
Every term links to the glossary.